Dr. Jeffrey Stewart Rubin, MD

Dr. Rubin practices at New York Eye and Ear Infirmary of Mount Sinai in New York, New York, part of Mount Sinai Health System.

Dr. Rubin's NPI, 1972663656, was assigned on December 11, 2006. Dr. Rubin graduated from State University of New York Downstate Medical Center in 1989. Dr. Rubin holds New York license 183574.

Dr. Rubin's primary practice is New York Eye and Ear Infirmary of Mount Sinai, at 230 Second Ave, New York, NY 10003 in New York County. The practice phone is (212) 979-4000. Dr. Rubin also practices at New York Eye & Ear Infirmary, 310 E 14th St, New York, NY 10003.

Dr. Rubin's primary practice is New York Eye and Ear Infirmary of Mount Sinai in New York, New York, part of Mount Sinai Health System. Dr. Rubin's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rubin practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Rubin's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Rubin is licensed in New York.

CMS data shows 50,156 Medicare services from Dr. Rubin across 26 procedure codes in 2024, for 1,495 Medicare patients. Medicare paid $3,254,110 for them. Every service was in an office.

CMS counts 1,495 Medicare patients who saw Dr. Rubin in 2024. The largest group is 75 to 84, with 551 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 49% are also on Medicaid. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rubin's median patient age at 74, with 60% women.

In 2024, Dr. Rubin wrote 2,441 Medicare Part D claims for 445 patients. 56% of them were for generic drugs. CMS names the drug for 2,359 of them, across 31 drugs with 11 or more claims each, at $307,290 in total drug cost. In 2023, CMS named 2,068 claims across 30 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Rubin for performance year 2024, reported individually. Dr. Rubin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 5 general payments to Dr. Rubin from 5 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 75% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $125.

Dr. Rubin graduated from State University of New York Downstate Medical Center in 1989.